Apogee Therapeutics, Inc. (APGE) intrinsic value & 10-year financials
Apogee Therapeutics, Inc. (APGE) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Revenue (FY2025)
- —
- Free cash flow (FY2025)
- -$232.6M
APGE 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$255.8M | -$4.22 | -$232.6M | — | — |
| FY2024 | — | -$182.1M | -$3.30 | -$172.3M | — | — |
| FY2023 | — | -$84.0M | -$3.36 | -$74.9M | — | — |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Apogee Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Apogee Therapeutics, Inc. 10-year average ROIC is N/A; capital efficiency cannot be assessed from the available history.
Apogee Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Apogee Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.